Aiforia's AI solutions to be integrated into Dedalus' pathology information systems

Translation: Original published in Finnish on 9/2/2025 at 9:01 am EEST.

Aiforia has announced a strategic alliance with the Dedalus Group, a European provider of healthcare and diagnostic software. Through this partnership, Aiforia's AI solutions will be integrated within Dedalus' pathology information systems. Aiforia's strategy is to build a broad customer base of clinical pathology laboratories, including through partnerships, and this announcement indicates that the company is continuing along this path. 

Partnership facilitates use of Aiforia's software in pathology laboratories

Dedalus is a European healthcare technology company headquartered in Italy with 5,700 laboratory and diagnostic center customers worldwide. Dedalus' product portfolio includes several software solutions required by hospitals that support the whole continuum of care, as stated in the press release. As part of the announced partnership, Aiforia's AI solutions will be integrated into Dedalus' InVitro Anatomic Pathology Information System.

In practice, using Aiforia's solutions always requires integration into pathology laboratories' central information systems (LIS/IMS). Therefore, we believe that a ready-made integration will accelerate the adoption of Aiforia's AI solutions in pathology laboratories that use Dedalus’ software. The partnership will also potentially provide Aiforia with new sales opportunities within the existing Dedalus software customer base, where the threshold for offering AI solutions as extensions is lower.

A slow adoption rate among its rapidly growing customer base has been a bottleneck for the company's growth, but this will generally be alleviated by broader integration with other systems. However, a key challenge to growth has been the slow progress of the company's customers in acquiring sample scanners, which are required to produce the digital sample images needed to use Aiforia's software. In our estimates, we assume the bottlenecks will gradually subside and the company will grow faster over the next 12–24 months. Therefore, the announcement has no impact on our estimates.